The participant has Modified Hoehn & Yahr stage 5 (or stage 5 at eather on-time or off-time for the participant with wearing off phenomenon). 
The participant has severe dyskinesia. 
The participant has unstable systemic disease. 
The participant has a Mini-Mental State Examinations (MMSE) score of <= 24. psychiatric disease. 
The participant has a history of clinically significant hypertension or other reactions associated with ingestion of tyramine-rich food. 
The participant has received neurosurgical intervention for Parkinson's disease (e.g., pallidotomy, thalamotomy, deep brain stimulation). 
The participant has received transcranial magnetic stimulation within 6 months.The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa within 90 days. 
The participant has received levodopa monotherapy, any psychoneurotic agent or antiemetic medication of dopamine agonist within 14 days. However, the participant has been receiving quetiapine or domperidone with a stable dose regimen for >= 14 days may be included in the study. 
The participant is required to take any of the excluded medications or treatments. 
The participant with laboratory data meeting any of the following: 
Creatinine >= 2 x upper limit of normal (ULN) 
Total bilirubin >= 2 x ULN 
ALT or AST >= 1.5 x ULN 
ALP >= 3 x ULN 
The participant has received any of the excluded medications or treatments during.       
    

NCT02337764_exc_T1
Measurement
Modified Hoehn & Yahr
NCT02337764_exc_T2
Value
stage 5
NCT02337764_exc_T3
Condition
wearing off phenomenon
NCT02337764_exc_T4
Temporal
at on-time
NCT02337764_exc_T5
Temporal
at off-time
NCT02337764_exc_T6
Value
stage 5
NCT02337764_exc_T7
Scope
at eather on-time or off-time
NCT02337764_exc_T8
Scope
stage 5 at eather on-time or off-time for the participant with wearing off phenomenon
NCT02337764_exc_T9
Condition
dyskinesia
NCT02337764_exc_T10
Qualifier
severe
NCT02337764_exc_T11
Condition
systemic disease
NCT02337764_exc_T13
Qualifier
unstable
NCT02337764_exc_T15
Measurement
Mini-Mental State Examinations (MMSE)
NCT02337764_exc_T16
Value
<= 24
NCT02337764_exc_T17
Condition
psychiatric disease
NCT02337764_exc_T19
Condition
hypertension
NCT02337764_exc_T20
Qualifier
clinically significant
NCT02337764_exc_T22
Condition
reactions associated with ingestion of tyramine-rich food
NCT02337764_exc_T24
Procedure
neurosurgical intervention
NCT02337764_exc_T25
Condition
Parkinson's disease
NCT02337764_exc_T26
Condition
pallidotomy
NCT02337764_exc_T27
Condition
thalamotomy
NCT02337764_exc_T28
Condition
deep brain stimulation
NCT02337764_exc_T29
Scope
pallidotomy, thalamotomy, deep brain stimulation
NCT02337764_exc_T30
Scope
neurosurgical intervention for Parkinson's disease
NCT02337764_exc_T31
Procedure
transcranial magnetic stimulation
NCT02337764_exc_T32
Temporal
within 6 months
NCT02337764_exc_T33
Drug
selegiline
NCT02337764_exc_T34
Drug
pethidine
NCT02337764_exc_T35
Drug
tramadol
NCT02337764_exc_T36
Drug
reserpine
NCT02337764_exc_T37
Drug
methyldopa
NCT02337764_exc_T38
Temporal
within 90 days
NCT02337764_exc_T39
Scope
selegiline, pethidine, tramadol, reserpine or methyldopa
NCT02337764_exc_T41
Procedure
levodopa monotherapy
NCT02337764_exc_T42
Drug
levodopa
NCT02337764_exc_T43
Drug
psychoneurotic agent
NCT02337764_exc_T44
Drug
antiemetic medication of dopamine agonist
NCT02337764_exc_T45
Temporal
within 14 days
NCT02337764_exc_T48
Scope
levodopa monotherapy, any psychoneurotic agent or antiemetic medication of dopamine agonist
NCT02337764_exc_T49
Drug
quetiapine
NCT02337764_exc_T50
Drug
domperidone
NCT02337764_exc_T51
Qualifier
stable dose
NCT02337764_exc_T52
Temporal
>= 14 days
NCT02337764_exc_T53
Scope
quetiapine or domperidone
NCT02337764_exc_T57
Measurement
Creatinine
NCT02337764_exc_T58
Value
>= 2 x upper limit of normal (ULN)
NCT02337764_exc_T59
Measurement
Total bilirubin
NCT02337764_exc_T60
Value
>= 2 x ULN
NCT02337764_exc_T61
Value
>= 1.5 x ULN
NCT02337764_exc_T62
Measurement
AST
NCT02337764_exc_T63
Measurement
ALT
NCT02337764_exc_T64
Scope
ALT or AST
NCT02337764_exc_T65
Measurement
ALP
NCT02337764_exc_T66
Value
>= 3 x ULN